Why AbbVie Stock Remains a Strong Buy Option for Investors
Sunday, 5 May 2024, 17:44
Resilience Amid Patent Cliff Impact
Despite Humira's patent expiration hitting AbbVie (NYSE: ABBV), the company's sales decline has been less severe than anticipated, reflecting operational strength.
Growth from Innovative Products
- Skyrizi: Rapidly growing psoriasis treatment with a market share of 35% in the U.S.
- Rinvoq: Showing a significant year-over-year increase in sales and a promising growth trajectory.
Stable Dividend Program
AbbVie's consistent dividend growth over 52 years and a current yield of 3.8% make it an attractive choice for income-focused investors.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.